H. Lundbeck A/S
HLUBF
Updated: 22/09/2026, 17:42:59
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. It operates through the following geographical segments: Europe, United States, and International Operations. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.
No summaries found.
- Share price
- $6.40
- Market cap
- $6.79B
- Exchange
- OTC
- Currency
- USD
- CEO
- Charl van Zyl
- Employees
- 5,214
- IPO date
- 18/07/2022
- Beta
- 0.257
- Last dividend
- $0.00
- Day range
- $5.37 – $6.40
- 52-week range
- $4.82 – $6.79
- 1-day performance
- 0.00%
- 1-year performance
- 32.78%
- Current drawdown (1Y)
- -5.70%
- CIK
- N/A
- CUSIP
- 405552100
- ISIN
- DK0061804697
- Created
- 07/12/2025, 04:33:15
- Last update
- 22/09/2026, 17:42:59
Track H. Lundbeck A/S with an AI analyst
See which prediction-market events move HLUBF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.